192 related articles for article (PubMed ID: 28009447)
61. Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma.
Ozsan GH; Micallef IN; Dispenzieri A; Kumar S; Lacy MQ; Dingli D; Hayman SR; Buadi FK; Wolf RC; Gastineau DA; Hogan WJ; Gertz MA
Am J Hematol; 2012 Jan; 87(1):1-4. PubMed ID: 21959988
[TBL] [Abstract][Full Text] [Related]
62. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
Bilgrami S; Bona RD; Edwards RL; Li Z; Naqvi B; Shaikh A; Furlong F; Fox J; Clive J; Tutschka PJ
Bone Marrow Transplant; 2001 Jul; 28(2):137-43. PubMed ID: 11509931
[TBL] [Abstract][Full Text] [Related]
63. The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF.
Hacıoğlu S; Sarı I; Doğu MH; Keskin A
Transfus Apher Sci; 2014 Feb; 50(1):71-4. PubMed ID: 24342458
[TBL] [Abstract][Full Text] [Related]
64. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
65. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
[TBL] [Abstract][Full Text] [Related]
66. Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma.
Chua CC; Lim HY; Chai KL; Ong J; Sim S; Wood C; Dickinson M; Campbell P; Hempton J; King H; Dowsing C; Bergin K; Muir S; Gibbs S; Grigg A
Bone Marrow Transplant; 2018 Sep; 53(9):1116-1123. PubMed ID: 29523889
[TBL] [Abstract][Full Text] [Related]
67. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
[TBL] [Abstract][Full Text] [Related]
68. Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma.
Corso A; Mangiacavalli S; Nosari A; Castagnola C; Zappasodi P; Cafro AM; Astori C; Bonfichi M; Varettoni M; Rusconi C; Troletti D; Pascutto C; Morra E; Lazzarino M;
Bone Marrow Transplant; 2005 Dec; 36(11):951-4. PubMed ID: 16184179
[TBL] [Abstract][Full Text] [Related]
69. Peripheral blood stem cell mobilization in multiple myeloma comparison of two consecutive regimens in a limited resources country.
Ben Abdejlil N; Belloumi D; Mâammar M; El Fatimi R; Torjman L; Lakhal A; Jenhani F; Hmida S; Ben Othman T; Ladeb S
Bone Marrow Transplant; 2017 Feb; 52(2):222-227. PubMed ID: 27775695
[TBL] [Abstract][Full Text] [Related]
70. Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy.
Sirohi B; Powles R; Cavanagh J; Oakervee H; Dyer P; Rintala T; Kulkarni S; Rudin C; Horton C; Treleaven J; Morgan G
Hematology; 2007 Apr; 12(2):113-5. PubMed ID: 17454191
[TBL] [Abstract][Full Text] [Related]
71. Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience.
Lamm W; Wohlfarth P; Bojic M; Schörgenhofer C; Drach J; Gisslinger H; Worel N; Schiefer A; Schulenburg A; Agis H; Kalhs P; Greinix HT; Schellongowski P; Rabitsch W
Oncology; 2015; 89(4):196-204. PubMed ID: 26228581
[TBL] [Abstract][Full Text] [Related]
72. High steady-state plasma levels of flt3-ligand in the peripheral blood is a good predictor for poor mobilization of CD34+ PBSC in patients undergoing high-dose chemotherapy and stem cell rescue.
Gazitt Y; Liu Q
J Hematother Stem Cell Res; 2000 Apr; 9(2):285-93. PubMed ID: 10813543
[TBL] [Abstract][Full Text] [Related]
73. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma.
Endo T; Sato N; Mogi Y; Koizumi K; Nishio M; Fujimoto K; Sakai T; Kumano K; Obara M; Ikeda H; Koike T
Bone Marrow Transplant; 2004 Apr; 33(7):703-7. PubMed ID: 14743197
[TBL] [Abstract][Full Text] [Related]
74. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'?
Powles R; Sirohi B; Kulkarni S; Treleaven J; Rudin C; Sankpal S; Goyal S; Horton C; Millar B; Saso R; Singhal S; Mehta J
Bone Marrow Transplant; 2002 Oct; 30(8):479-84. PubMed ID: 12379885
[TBL] [Abstract][Full Text] [Related]
75. Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide.
Hart C; Blank C; Krause SW; Andreesen R; Hennemann B
Ann Hematol; 2007 Aug; 86(8):575-81. PubMed ID: 17476507
[TBL] [Abstract][Full Text] [Related]
76. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF.
Ozcelik T; Topcuoglu P; Beksac M; Ozcan M; Arat M; Biyikli Z; Bakanay SM; Ilhan O; Gurman G; Arslan O; Demirer T
Bone Marrow Transplant; 2009 Dec; 44(12):779-83. PubMed ID: 19597420
[TBL] [Abstract][Full Text] [Related]
77. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Moreb JS; Byrne M; Shugarman I; Zou F; Xiong S; May WS; Norkin M; Hiemenz J; Brown R; Cogle C; Wingard JR; Hsu JW
J Clin Apher; 2018 Feb; 33(1):29-37. PubMed ID: 28556233
[TBL] [Abstract][Full Text] [Related]
78. Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma.
Jelinek T; Adamusova L; Popkova T; Tvrda I; Smejkalova J; Simicek M; Salounova D; Kascak M; Mihalyova J; Plonkova H; Duras J; Navratil M; Hajek R; Koristek Z
Bone Marrow Transplant; 2019 Jul; 54(7):1107-1114. PubMed ID: 30459429
[TBL] [Abstract][Full Text] [Related]
79. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.
Nazha A; Cook R; Vogl DT; Mangan PA; Gardler M; Hummel K; Cunningham K; Luger SM; Porter DL; Schuster S; O'Doherty U; Siegel D; Stadtmauer EA
Bone Marrow Transplant; 2011 Jan; 46(1):59-63. PubMed ID: 20421869
[TBL] [Abstract][Full Text] [Related]
80. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.
Kamezaki K; Kikushige Y; Numata A; Miyamoto T; Takase K; Henzan H; Aoki K; Kato K; Nonami A; Kamimura T; Arima F; Takenaka K; Harada N; Fukuda T; Hayashi S; Ohno Y; Eto T; Harada M; Nagafuji K
Bone Marrow Transplant; 2007 May; 39(9):523-7. PubMed ID: 17369863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]